Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide.
暂无分享,去创建一个
T. Ishikawa | N. Hiramoto | M. Nishikubo | Y. Shimomura | S. Yoshioka | Daishi Nakagawa | Y. Nagai | N. Yonetani | K. Kamijo | Satoshi Mitsuyuki | Ryusuke Yamamoto | Tomoyo Kubo | Naoki Okada
[1] K. Akashi,et al. Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis , 2022, International Journal of Hematology.
[2] E. Shpall,et al. Refractory and Resistant Cytomegalovirus after Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] M. Perales,et al. Post-Transplant Cyclophosphamide (PTCy) is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis. , 2021, Blood.
[4] T. Luft,et al. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data , 2020, Annals of Hematology.
[5] K. Akashi,et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data , 2020, Bone Marrow Transplantation.
[6] Ji Lin,et al. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies , 2020, Annals of Hematology.
[7] N. Kröger,et al. Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.
[8] H. Chu,et al. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. , 2019, Blood advances.
[9] A. A. Ribeiro,et al. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] B. Sandmaier,et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. , 2019, Blood advances.
[11] H. Einsele,et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT , 2018, Haematologica.
[12] R. Vij,et al. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide , 2016, Haematologica.
[13] M. Norkin,et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. , 2016, Blood.
[14] H. Einsele,et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] M. Horowitz,et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. , 2014, Blood.
[16] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[17] Allen R. Chen,et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] M. Sorror,et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.
[19] K. Matsuo,et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). , 2003, Blood.
[20] M. Leffell,et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] K. Takenaka,et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors , 1997, Bone Marrow Transplantation.